Ovid Therapeutics Inc. (OVID) SEC Filing 8-K Material Event for the period ending Thursday, June 27, 2019

Ovid Therapeutics Inc.

CIK: 1636651 Ticker: OVID

View differences made from one to another to evaluate Ovid Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ovid Therapeutics Inc..


Assess how Ovid Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ovid Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Ovid Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Ticker: OVID
CIK: 1636651
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-023703
Submitted to the SEC: Thu Jun 27 2019 12:04:02 PM EST
Accepted by the SEC: Thu Jun 27 2019
Period: Thursday, June 27, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: